{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P18621",
      "entity_text" : "PD-1",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q7Z6A9",
      "entity_text" : "BTLA",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "As a result, engagement of the BTLA pathway is likely to mask the phenotypic consequences of blocking the PD-1 pathway, and coadministration of PD-1 and BTLA antibodies to patients should augment the therapeutic benefit of PD-1 blockade, as illustrated by in vivo studies in the mouse and in vitro studies in humans.",
  "reading_complete" : "2020-08-08T15:08:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T15:02:10Z",
  "trigger" : "augment",
  "evidence" : [ "BTLA antibodies to patients should augment the therapeutic benefit of PD-1" ],
  "pmc_id" : "6581740",
  "score" : 0
}